<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00052299</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-06012</org_study_id>
    <secondary_id>EORTC-06012</secondary_id>
    <secondary_id>AML-17</secondary_id>
    <secondary_id>GIMEMA-AML-17</secondary_id>
    <nct_id>NCT00052299</nct_id>
  </id_info>
  <brief_title>Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia</brief_title>
  <acronym>AML-17</acronym>
  <official_title>Gemtuzumab Ozogamicin (GO) Combined With Standard Intensive Chemotherapy Versus Standard Intensive Chemotherapy Alone For Induction/Consolidation In Patients 61-75 Years Old With Previously Untreated AML: A Randomized Phase III Trial (AML-17) Of The EORTC-LG and the GIMEMA-ALWP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Monoclonal antibodies can locate cancer cells and either kill
      them or deliver cancer-killing substances to them without harming normal cells. It is not yet
      known if combining combination chemotherapy with monoclonal antibody therapy will kill more
      cancer cells.

      PURPOSE: Randomized phase III trial to determine the effectiveness of combination
      chemotherapy with or without gemtuzumab ozogamicin in treating patients who have acute
      myeloid leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the antileukemic activity of standard induction chemotherapy with or without
           gemtuzumab ozogamicin in elderly patients with previously untreated acute myeloid
           leukemia.

        -  Determine the overall survival of patients treated with these regimens.

        -  Determine the rate of response, disease-free survival, event-free survival, incidence of
           relapse, and incidence of death of patients treated with these regimens.

        -  Determine the rate, type, and grade of toxicity of these regimens in these patients.

      OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified
      according to age (61-69 vs 70-75), CD33 positivity (less than 5% vs 5-19% vs 20-80% vs more
      than 80% vs unknown), initial WBC before hydroxyurea administration if needed (less than
      30,000/mm^3 vs at least 30,000/mm^3), and participating center. Patients are randomized to 1
      of 2 treatment arms.

        -  Arm I:

             -  Induction (phase I): Patients receive gemtuzumab ozogamicin IV over 2 hours on days
                1 and 15.

             -  Induction (phase II/MICE regimen): Beginning between days 50 and 53, patients
                receive mitoxantrone IV over 30 minutes on days 1, 3, and 5; etoposide IV over 1
                hour on days 1-3; and cytarabine IV continuously on days 1-7. Bone marrow
                evaluation is performed on day 29. Patients with partial remission (PR) receive a
                second course of MICE chemotherapy regimen. Patients with complete remission (CR)
                after 1 or 2 courses of MICE regimen proceed to consolidation therapy. Patients
                with progressive disease go off therapy.

             -  Consolidation: Beginning within 4 weeks of documentation of CR, patients receive
                gemtuzumab ozogamicin IV over 2 hours on day 0; idarubicin IV on days 1, 3, and 5;
                etoposide IV over 1 hour on days 1-3; and cytarabine IV continuously on days 1-5.
                After at least day 30, patients receive a second consolidation course in the
                absence of disease progression or unacceptable toxicity.

        -  Arm II:

             -  Induction (MICE regimen): Patients receive mitoxantrone, etoposide, and cytarabine
                as in arm I induction. Bone marrow evaluation is performed on day 29. Patients with
                PR receive a second course of MICE chemotherapy regimen. Patients with CR after 1
                or 2 courses of MICE regimen proceed to consolidation therapy. Patients with
                progressive disease go off therapy.

             -  Consolidation: Patients receive idarubicin, etoposide, and cytarabine as in arm I
                consolidation.

      Patients are followed monthly for 1 year, every 3 months for 2 years, and then every 6 months
      thereafter.

      PROJECTED ACCRUAL: A total of 450 patients (225 per treatment arm) will be accrued for this
      study within 3.75 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response (complete remission [CR] or complete remission with incomplete recovery of platelet count [CRp]) rate after induction</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival after CR/CRp</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of relapse after CR/CRp</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of death without relapse after CR/CRp</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity (highest grade) assessed by International Working Group CTC v2.0</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">472</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>ARM A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GO + MICE for remission induction followed by GO + mini-ICE for consolidation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MICE for remission induction followed by mini-ICE for consolidation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <arm_group_label>ARM A</arm_group_label>
    <arm_group_label>ARM B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <arm_group_label>ARM A</arm_group_label>
    <arm_group_label>ARM B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemtuzumab ozogamicin</intervention_name>
    <arm_group_label>ARM A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>idarubicin</intervention_name>
    <arm_group_label>ARM A</arm_group_label>
    <arm_group_label>ARM B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone hydrochloride</intervention_name>
    <arm_group_label>ARM A</arm_group_label>
    <arm_group_label>ARM B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of acute myeloid leukemia (AML)

               -  Bone marrow blasts at least 20% by bone marrow aspiration or biopsy

               -  FAB subtypes M0-M2 and M4-M7

                    -  No acute promyelocytic leukemia (FAB subtype M3)

          -  Previously untreated primary or secondary AML, including AML after myelodysplastic
             syndromes

               -  Hydroxyurea and/or corticosteroid therapy for no more than 14 days allowed

          -  No blast crisis of chronic myelogenous leukemia

          -  No AML supervening after other myeloproliferative diseases

          -  No active CNS leukemia

        PATIENT CHARACTERISTICS:

        Age

          -  61 to 75

        Performance status

          -  WHO 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  WBC less than 30,000/mm^3 (pretreatment with hydroxyurea for no more than 14 days
             allowed)

        Hepatic

          -  Bilirubin no greater than 3 times upper limit of normal (ULN)

        Renal

          -  Creatinine no greater than 3 times ULN

        Cardiovascular

          -  No concurrent severe cardiovascular disease

          -  No arrhythmias requiring chronic treatment

          -  No congestive heart failure

          -  No symptomatic ischemic heart disease

        Pulmonary

          -  No severe pulmonary dysfunction (CTC grade 3-4)

        Other

          -  HIV negative

          -  No other uncontrolled infection

          -  No other concurrent malignant disease

          -  No severe concurrent neurological or psychiatric disease

          -  No prior alcohol abuse

          -  No psychological, familial, sociological, or geographical condition that would
             preclude study participation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No concurrent hematopoietic growth factors (filgrastim [G-CSF] or sargramostim
             [GM-CSF]) except for life-threatening infection due to neutropenia

        Chemotherapy

          -  See Disease Characteristics

        Endocrine therapy

          -  See Disease Characteristics

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified

        Other

          -  No prior enrollment in this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>61 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergio Amadori, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Azienda Ospedallera Universitaria - Policlinico Tor Vergata, Roma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>A. oe. Krankenhaus der Barmherzigen Schwestern Kinderabteilung</name>
      <address>
        <city>Linz</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus - Universitatskliniken</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Brugmann</name>
      <address>
        <city>Brussels</city>
        <zip>B 1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de Jolimont</name>
      <address>
        <city>Haine Saint Paul</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Liege - Domaine Universitaire du Sart Tilman</name>
      <address>
        <city>Liege</city>
        <zip>B-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Peltzer-La Tourelle</name>
      <address>
        <city>Verviers</city>
        <zip>B-4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu de Paris</name>
      <address>
        <city>Paris</city>
        <zip>75181</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Albert - Ludwigs - Universitaet Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>D-79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruprecht - Karls - Universitaet Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest German Cancer Center at Eberhard-Karls-University</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita Degli Studi di Bari</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Di Bologna Policlinico S. Orsola - Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria di Bolzano</name>
      <address>
        <city>Bolzano</city>
        <zip>39100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Binaghi</name>
      <address>
        <city>Cagliari</city>
        <zip>090100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Oncologico A. Businco</name>
      <address>
        <city>Cagliari</city>
        <zip>09121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Ferrarotto</name>
      <address>
        <city>Catania</city>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale A. Pugliese</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Istituti Ospitalieri</name>
      <address>
        <city>Cremona</city>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita di Ferrara</name>
      <address>
        <city>Ferrara</city>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Antonio Abate</name>
      <address>
        <city>Gallarate Varese</city>
        <zip>21013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Martino</name>
      <address>
        <city>Genoa</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita degli Studi di Messina</name>
      <address>
        <city>Messina</city>
        <zip>98122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Papardo</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Umberto I</name>
      <address>
        <city>Mestre</city>
        <zip>30174</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera - Universitaria di Modena</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;A. Cardarelli&quot;</name>
      <address>
        <city>Naples</city>
        <zip>80127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federico II University Medical School</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Maggiore Della Carita</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedale S. Luigi at University of Torino</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Policlinico Paolo Giaccone</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Cervello</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale La Maddalena - Palermo</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perugia Regional Cancer Center</name>
      <address>
        <city>Perugia</city>
        <zip>06122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedale - d &quot;S. Salvatore&quot;</name>
      <address>
        <city>Pesaro</city>
        <zip>I-61100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Pescara</name>
      <address>
        <city>Pescara</city>
        <zip>65100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Sant' Eugenio</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Libero Istituto Universitario Campus Bio-Medico</name>
      <address>
        <city>Rome</city>
        <zip>00155</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita Degli Studi &quot;La Sapeinza&quot;</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico A. Gemelli - Universita Cattolica del Sacro Cuore</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. San Giovanni-Addolorata Hospital</name>
      <address>
        <city>Rome</city>
        <zip>00184</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia Universita - University di Sassari</name>
      <address>
        <city>Sassari</city>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico G. B. Rossi - Borgo Roma</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Bortolo</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>'s-Hertogenbosch</city>
        <zip>5211 NL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1091 HA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum St. Radboud - Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum - Veldhoven</name>
      <address>
        <city>Veldhoven</city>
        <zip>5500 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Escolar San Joao</name>
      <address>
        <city>Porto</city>
        <zip>4200</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Portugal</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2003</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 24, 2012</last_update_submitted>
  <last_update_submitted_qc>August 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult acute erythroid leukemia (M6)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Gemtuzumab</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

